Buchumschlag

Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs

Objective. To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Behrens, Frank (VerfasserIn) , Lorenz, Hanns-Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 1, 2018
In: The journal of rheumatology
Year: 2018, Jahrgang: 45, Heft: 6, Pages: 802-810
ISSN:1499-2752
DOI:10.3899/jrheum.170932
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3899/jrheum.170932
Verlag, lizenzpflichtig, Volltext: http://www.jrheum.org/content/45/6/802
Volltext
Verfasserangaben:Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann and Hanns-Martin Lorenz
Beschreibung
Zusammenfassung:Objective. To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life simultaneously. - Methods. A prospective, multicenter, 52-week observational study in patients with active PsA evaluated treatment with ETN in clinical practice (ClinicalTrials.gov: NCT00293722). This analysis assessed simultaneous achievement of 3 treatment targets: low disease activity (LDA) based on 28-joint count Disease Activity Score (DAS28); body surface area (BSA) involvement ≤ 3%; and a score > 45 on the Medical Outcomes Study Short Form-12 (SF-12) physical component summary. - Results. Of 579 patients, 380 received ETN monotherapy and 199 received combination ETN plus csDMARD. At 52 weeks, data for all 3 disease domains were available for 251 patients receiving monotherapy and 151 receiving combination therapy. In the monotherapy and combination therapy groups, 61 (24.3%) and 37 (24.5%) patients, respectively, achieved all 3 treatment targets simultaneously. A significantly greater proportion of patients receiving monotherapy versus combination therapy achieved SF-12 > 45 (43.0% vs 31.8%; p < 0.05) and DAS28 LDA (72.5% vs 62.3%; p < 0.05). Conversely, BSA ≤ 3% was reached by a significantly greater proportion receiving combination therapy (75.5% vs 56.6%; p < 0.001). However, baseline BSA involvement was higher for the monotherapy group. - Conclusion. While nearly half the patients achieved arthritis and psoriasis treatment targets simultaneously and one-fourth reached all 3 treatment targets, combining ETN and csDMARD did not substantially improve clinical response compared with ETN monotherapy in this real-world PsA patient population.
Beschreibung:Gesehen am 10.03.2020
Beschreibung:Online Resource
ISSN:1499-2752
DOI:10.3899/jrheum.170932

Ähnliche Einträge